

## Index

- A1C, S5, S6, S7, S12, S20, S24, S25, S26, S27, S56, S57, S59  
 advantages of, S22  
 age and, S23  
 alternatives to, **S112**  
 cardiovascular disease and, S116–S117  
 by CGM, **S112, S113–S114**  
 confirming diagnosis with, S22  
 correlation with BGM, S112  
 diabetes distress and, S94  
 equivalent eAG levels, S112  
 for diabetes screening and diagnosis, S21–S22  
 glycemic assessment by, S7, **S112**  
 hemoglobinopathies and, S22  
 in children, **S30, S263–S264, S268, S269, S270–S271**  
 in cystic fibrosis-related disease, S31  
 in gestational diabetes mellitus, S34–S35  
 in hyperglycemia, S64  
 in people with HIV, **S30**  
 in preclinical type 1 diabetes, S43  
 in staging type 1 diabetes, S24, S25  
 limitations, S7, S112  
 microvascular complications and, **S115–S116**  
 in prediabetes, S27–S28, S43–S44  
 in pregnancy, S22, **S285–S286**  
 other conditions affecting, S22  
 periodontal disease and, S69  
 point-of-care assays S21, S22, S112  
 race/ethnicity and, **S22, S79**  
 recommendations, **S21–S22**  
 serum glycosylated protein assays versus, **S112**  
 setting and modifying goals for, **S113–S118**  
 sleep and, S97
- AABBCC approach, S23  
 acarbose, S68, S154, S174  
 access to care, S14  
 access to insulin, S308  
 ACCORD study, S60, S64, S116, S117, S118, S181, S182, S183, S192, S222, S236, S246  
 ACE inhibitors, S9, S56, S184, S185, S186, S195, S202, **S205, S220, S222, S223–S224, S266, S271, S283, S289**  
 acellular matrix tissues, S40  
 acute kidney injury, S151–S152, S181, S183, **S186, S222**  
 ADA consensus reports, S4, S9, S32, S54, S80, S88, S113, S147, S160, S164, S165, S179, S197, S202, S245  
 ADA evidence-grading system, S3  
 ADA Professional Practice Committee, S1, S2, S309  
 ADA scientific reviews, S4  
 ADA statements, S4  
 ADAG study, S112  
 Addison disease, S24, S59, S265  
 adolescents. *see* children and adolescents.  
 adrenal insufficiency, primary, S59, S265  
 adult-onset diabetes. *see* Type 2 diabetes.  
 ADVANCE trial, S64, S116, S117, S118, S181, S182, S183  
 advocacy statements, **S307–S308**  
 care of young children with diabetes in the childcare setting, S307  
 diabetes and driving, S308  
 diabetes and employment, S308  
 diabetes care in the school setting, S308  
 insulin access and affordability, S308  
 affordability, of insulin, S308  
 Affordable Care Act, S14, S274  
 African Americans, S15, S22, S23, S26, S27, S28, S29, S87, S221  
 age  
 aspirin use and, S193–S194  
 effect on A1C, **S23**  
 in diabetes diagnosis and classification, S23–S29  
 risk factor for diabetes, S29, **S30**  
 statin treatment and, S188  
 agricultural workers, migrant, S15–S16  
 AIM-HIGH trial, S192  
 albiglutide, S204, S205, S206  
 albuminuria, S9, S85, S87, S90, S119, S165, S180, S182, S185, S186, S193, S195, S199, S205, S207, 209–210, S219, S220, **S221, S222–S227, S265, S267, S273**  
 alcohol intake, S6, S55, S59, S65, S81, **S86, S98, S119, S154, S184, S191, S235, S237, S283**  
 algorithms  
 for diabetic retinopathy screening, S232  
 insulin dosing, S126, S133, S135, S222, S246, S288, S296  
 to predict hypoglycemia, S300  
 alirocumab, S188, S189, S190  
 alogliptin, S172, S196, S197, S206, S299  
 alpha-glucosidase inhibitors, S46, S148, S172  
 alpha-lipoic acid, S237  
 ambulatory glucose profile (AGP), S113, S114, S115, S131, S286  
 amputation, foot, S9, S64, S202, S203, S234, S237, S238, S239, S240  
 analogs. *see* insulin analogs.  
 angiotensin receptor blockers (ARBs), S9, S56, S184, S222, S266, S267, S271, S284, S289  
 anti-VEGF agents, **S233–S234**  
 antiplatelet agents, **S192–S194, S247**  
 antipsychotics, S28, S96, S148  
 antiretroviral therapies, S27, S30  
 anxiety disorders, S15, S56, S91, S92, S93, **S94, S134, S154, S234, S263**  
 ARRIVE trial, S193  
 artificial intelligence algorithms, for diabetic retinopathy, S232  
 ASCEND trial, S85, S193  
 Asian Americans, S26, S27, S28, S29, S45, S149, S153  
 aspart, S170, S173, S250  
 aspirin therapy, S10, **S192–S194, S233, S248, S289**  
 ASPREE trial, S193  
 atenolol, S237, S289  
 atherosclerotic cardiovascular disease (ASCVD), S57, S165, S166, S168, S169, **S179–S218**  
 atorvastatin, S188, S190  
 autoimmune diseases, S23, S26, **S59, S265–S266, S289**  
 autoimmune type 1 diabetes, S23, S24, S32, S268  
 autologous blood products, S240  
 automated insulin delivery (AID) systems, S7, S8, S83, S84, S97, S116, S119, S120, S126, S127, **S133–S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297**  
 autonomic neuropathy, diabetic, S59, S89, **S90, S181, S234, S235, S301**  
 balloons, implanted gastric, S149  
 bariatric surgery. *see* metabolic surgery.  
 basal insulin, S10, S119, **S129, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, S170, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302**  
 bedtime dosing  
 of antihypertensives, **S186**  
 of insulin, S155, S162, S163, S248  
 behavioral therapy, **S147–S148**  
 behaviors, changes in, S6, **S77–S110**  
 cost considerations for medication-taking, S6, **S13–S14**  
 diabetes self-management education and support, **S77–S80**  
 for diabetes prevention, **S44–S46**  
 medical nutrition therapy, **S80–S86**  
 physical activity, **S86–S90**  
 in gestational diabetes, **S287**  
 psychosocial care, **S91–S98**  
 smoking cessation, **S90–S91**  
 supporting positive health behaviors, **S91**  
 well-being and, S13  
 bempedoic acid, S8, S187, **S191**  
 beta-carotene, S81, S85  
 beta-cell replacement therapy, S161, S164  
 biguanides, S172  
 bioengineered allogeneic cellular therapies, S240  
 bladder dysfunction, S235, S284  
 Blood Glucose Awareness Training, S121  
 blood glucose monitoring (BGM), S53, **S127–S129, S160, S163**  
 in hospitalized patients, **S297**  
 continuous glucose monitoring, **S129–S132**  
 correlation with A1C, **S112**  
 devices for, **S126–S127**  
 during pregnancy, S284, **S285**  
 in children and adolescents, S264, S269, S271  
 in intensive insulin regimens, **S129**  
 in older adults, S246, S251  
 in people on basal insulin, oral agents, or noninsulin injectables, **S129**  
 in schools, **S127**  
 inaccuracy of, **S129**  
 interfering substances, S129  
 meter standards, **S128**  
 optimizing device use, **S128–S129**  
 surveillance of, S128  
 blood pressure control. *see also* hypertension, S180–S186, S205, S219, S222  
 body mass index (BMI), S7, S10, S23, S25, S26, S31, S45, S46, S47, S56, S59, S87, S88, S146, S149, S223,  
 COVID-19 mortality and, S62  
 effects of metformin use in pregnancy on, S287, S288, S290  
 for metabolic surgery, S150, S153, S271  
 in obese patients, S146–S147, S148  
 in screening asymptomatic adults, S27  
 in screening asymptomatic children, S27, S268  
 postpartum, S290  
 bone fracture risk, S59–S62, S68  
 bone-strengthening activities, S86, S87, S261, S270

- breastfeeding. *see* lactation.  
bromocriptine, S148, S172
- calcium channel blockers, S186, S224  
canagliflozin, S62, S169, S172, S197, S200, S203, S205, S206, S207, S224, S225  
cancer, risk in diabetics, **S62**  
cannabis, S6, **S90–S91**,  
CANVAS study, S62, S197, S200–S201, S203, S207, S224, S226  
CANVAS-R study, S203  
capsaicin, topical, **S236**  
carbamazepine, S236  
carbohydrate intake, S26, S81, S84, S86, S158, S162–S163, S261–S262, S286  
cardiac autonomic neuropathy, diabetic, **S235**  
cardiac function testing, **S272–S273**  
cardiovascular disease, S2, S7, **S179–S218**  
antiplatelet agents, **S192–S194**  
cardiac testing, **S195–S196**  
heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227  
hypertension/blood pressure control, **S180–S186**  
lifestyle and pharmacologic interventions, **S202–S205**  
lipid management, **S186–S187**  
prevention of, **S47**  
risk calculator, **S180**  
screening, **S194–S195**  
statin treatment, **S187–S192**  
treatment, **S196**  
cardiovascular risk, S14, S16, S27, S33, S47, S54, S60, S63, S65, S67, S68, S85, S87, S88, S116–S117, S146, S153, S164–S165, S168, S179, **S180–S184**, S187, S188, S190, S191, S193, S194, S195–S197, S202, S204, S205, S206, S208, S210, S219–S220, S222, S223, S226, S235, S236, S245, S247, S248, S259, S261, **S266–S267**,  
care delivery systems, S5  
access to care and quality improvement, S14  
behaviors and well-being, S13  
care teams, S13  
chronic care model, S12  
medication cost considerations, S13–S14  
six core elements, S12  
system-level improvement strategies, S12–S13  
telehealth, S13  
care teams, **S13**, S91, S92, S93, S95, S127, S136, S273  
CARMELINA trial, S196, S206  
CAROLINA trial, S196, S202  
celiac disease, S24, S59, S61, S259, **S265–S266**  
CHAP trial, S184, S289  
Charcot neuropathy, S9, S88, S90, S237, S238, S239  
childcare, S10, S120, **S262**, S307  
children and adolescents, S7, S9, **S258–S281**  
A1C in, **S30**, S263–S264, S268, S269, S270–S271  
asymptomatic, risk-based screening in, S27  
cystic fibrosis-related diabetes in, S6, S21, S23, S31, S111, S135, S258, S268, S284  
diabetes care in childcare settings, S10, S120, **S262**, S307  
diabetes care in school setting, **S127**, S261, **S262**, S263, S268, S308  
insulin pumps in, S7, S263, S270  
maturity-onset diabetes of the young (MODY), S22, **S32–S33**  
monogenic diabetes syndromes, **S32–S34**  
neonatal diabetes, S22, **S32**, **S33**  
physical activity in, S45, S86, **S87**  
screening for type 1 risk, S26, **S267**  
screening for prediabetes and type 2, S27, **S30**, **S268**  
substance abuse, S273  
transition from pediatric to adult care, **S273–S274**  
type 1 diabetes in, S14, S23, S24, S46, **S261–S268**  
type 2 diabetes in, **S268–S273**  
CHIPS trial, S184, S289  
cholesterol lowering therapy, S9, S56, S187, S190, S191  
chronic care model, S11 **S12**, S52, S269  
chronic kidney disease, diabetic, S8, S9, S32, S53, S54, S56, S57, S66, S87, S117, S119, S120, S161, S164, S165, S166, S180, S195, S199, **S209–S210**, **S219–S230**, S244, S248, S249, S252  
acute kidney injury, S151–S152, S181, S183, **S186**, **S222**  
assessing albuminuria and GFR, **S221**  
diagnosis, **S221**  
epidemiology, **S221**  
interventions for, **S223–S227**  
referral to nephrologist, **S227**  
risk of progression, S223, S224, S226  
screening recommendations, **S219**  
staging, S221  
surveillance, **S222–S223**  
treatment recommendations, **S219–S221**  
chrononutrition, S83  
classification, S5, **S22–S23**  
clonidine, S237, S289  
clopidogrel, S193, S194  
closed-loop systems, S135  
do-it-yourself, **S135**  
hybrid, S7, S8, S135, S159, S162, S246, S297  
coaching, online, S78, S136  
cognitive capacity/impairment, S96–S97  
colesevelam, S148, S172  
collaborative care, **S52–S54**, S94, S95, S197–S198  
collagen vascular diseases, S59  
combination therapy, S8, S164, S165, **S168–S169**, **S190–S191**, **S192**, S193, **S194**, S205, S237, S252  
community health workers, S14, S16, S45, S52, S79, S91, S169  
community screening, **S30**  
community support, S5, S14, **S16**, S97, S262, S273  
comorbidities, S6, S9, S12, S23, S32, **S43**, S47, **S52–S76**  
assessment of, **S59–S69**  
autoimmune diseases, S59  
bone health and fractures, S59–S62  
cancer, **S62**  
cognitive impairment/dementia, **S62**  
COVID-19, **S62–S64**  
disability, **S64**  
hepatitis C, **S64**  
hyperglycemia, **S64**  
hypoglycemia, **S64–S65**  
low testosterone in men, **S65**  
nonalcoholic fatty liver disease, **S65–S68**  
obstructive sleep apnea, **S68–S69**  
pancreatitis, **S69**  
periodontal disease, **S69**  
prevention or delay of, S6, **S43–S51**  
sensory impairment, S77  
COMPASS trial, S194  
computerized prescriber order entry (CPOE), S298  
CONCEPTT study, S285, S286  
connected insulin pens, S126, S127, S133, S161, S263  
continuous glucose monitoring (CGM), S7, S8, S9, S10, S21, S31, S53, S55, S56, S78, S83, S84, S95, S111, **S113–S117**, S126–S127, S128, S159, S162–S163, S166  
ambulatory glucose profile in, S113, S114, S115, S131, S286  
assessment of glycemic status with, **S113**  
benefits of, S130  
devices for, **S129–S130**  
in hospitalized patients, S136, **S297–S298**, **S299–S300**  
in hypoglycemia prevention, S118, S121  
in older adults, **S246**, S253  
in pediatric type 1 diabetes, S263–S265  
in pediatric type 2 diabetes, S269–S271  
in pregnancy, S131–S132, S284, **S286**  
initiation of device use, S127  
interfering substances, S132  
intermittently scanned devices, S7, S78, S94, S129–S130, **S131**, S263, S264, S269  
real-time, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297  
side effects, S132  
continuous subcutaneous insulin infusion (CSII), S126, S127, S129–S130, S133, S135, S159, S160, S161  
contraception, S149, S152, S259, S260, S263, S266, S267, S271, S272, S273, S282–S283, S284, S289, **S291**  
coronary artery disease, S88, S184, S185, S186, S194, S197, S202, S205  
cost considerations, **S13–S14**, S149–S153, S159–S160, S165, S169, S170, S173  
counterfeit test strips, S128  
COVID-19, S5, S6, S26, S28, **S54–S56**, **S62–S64**, S80, S297  
COVID-19 vaccines, S56, S58, S64–S65, S285  
CRENDENCE study, S62, S200–S201, S203, S207, S225, S226  
cystatin C, S221  
cystic fibrosis-related diabetes, S6, S21, S23, S31, S111, S135, S258, S268, S284  
Da Qing Diabetes Prevention Outcome Study, S44, S47, S48  
DAPA-CKD study, S200–S201, S203, S225, S226  
DAPA-HF study, S200–S201, S203, S206, S207  
dapagliflozin, S62, S63, S169, S172, S200–S201, S203, S204, S206, S207, S225, S226  
DARE-19 study, S63  
DASH diet, S45, S82, S184, S186  
DECLARE-TIMI 58 study, S200–S201, S203, S207, S226  
degludec, S159, S170, S172, S174, S250, S298  
delay, of symptomatic type 1 diabetes, S48  
delay, of type 2 diabetes, S5–S6, **S43–S51**  
lifestyle behavior change, **S44–S46**  
person-centered care goals, **S47–S48**  
pharmacologic interventions, **S46–S47**  
recommendations, S43, S44, S46, S4, S487  
of vascular disease and mortality, **S47**  
DELIVER study, S200–S201, S204, S207  
dementia, in diabetics, S62, S64, S65, S69, S96, S119, S192, S245–S246

- demographics, of diabetes care, S12–S14  
 dental practices, screening in, S30, S55, S57  
 depression, S7, S15, S56, S88, S91, S92, S93, S94, **S95**, S97, S134, S150, S154, S234, S236, S244, S245, S248, S251, S263, S273  
 detemir, S162, S170, S173, S250  
 devices. *see* technology.  
 Diabetes Control and Complications Trial (DCCT), S21, S22, S69, S116, S159, S264, S267  
 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S69, S117, S120, S246  
 diabetes distress, S6, S9, S12, S15, S56, S91, S92, **S93–S94**, S130, S159, S262, S263, S273, S303  
 diabetes medical management plan (DMMP), for students, S127  
 Diabetes Prevention Impact Tool Kit, S45  
 Diabetes Prevention Program (DPP), S27, S28, **S44**, S45, S46, S48, S86, S136  
 Diabetes Prevention Program Outcomes Study (DPPOS), S28, S44, S46, S48, S47, S86, S168  
 Diabetes Prevention Recognition Program (DPRP), S46  
 diabetes self-management education and support (DSMES), S6, S13, S16, S54, **S77–S80**, S82, S94, S172  
 diabetes technology. *see* technology, diabetes.  
 diabetic ketoacidosis, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, **S301–S302**  
 diabetic kidney disease. *see also* chronic kidney disease.  
 dietary protein and, S75  
 diagnosis, S221  
 physical activity and, **S90**  
 finerenone in, S202, **S206**, **S209–S210**, S225, S226–S227  
 glucose-lowering medications for, S224–S227  
 multiple drug therapy, S186  
 prevention, S222  
 screening for complications of, S223  
 Diabetic Retinopathy Study (DRS), S234  
 diagnosis, S5, S6, **S20–S37**  
   confirmation of, S22  
   criteria for, S21  
   cystic fibrosis-related, S22, **S31**  
   diabetic kidney disease, S221  
   diagnostic tests, S20–S22  
   gestational diabetes, S34–S37  
   maturity onset diabetes of the young (MODY), S32, S33  
   monogenic diabetes syndromes, **S32–S34**  
   neonatal diabetes, S32  
   posttransplantation diabetes mellitus, **S31–S32**  
   prediabetes and type 2, **S26–S31**  
   type 1, **S24–S26**,  
 diagnostic tests, S20–S22  
   A1C use as, **S21–S22**  
   confirmation of, S22  
   criteria for, S21  
   fasting plasma glucose (FPG) test, S20, **S21**, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S171  
   oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290  
 plasma glucose test, 2-h, S20, **S21**, S23, S24, S26, S27, S30, S33, S35  
 diet, *see* Medical nutrition therapy.  
 Dietary Reference Intakes, S287  
 DIAMOND trial, S246  
 digital health technology, **S136**  
 dipeptidyl peptidase 4 (DPP4) inhibitors, S62, S68, S148, S166, S167, S168, S172, S196, S202, S250, S252, S298  
 disordered eating behavior, S56, S82, S84, S91, S92, S93, **S95–S96**, S261, S262, S263, S273, do-it-yourself systems, **S135**, S159  
 domperidone, S237  
 Dose Adjusted for Normal Eating (DAFNE), S121  
 DRCR Retina Network, S233  
 driving, and diabetes, S308  
 droxidopa, S237  
 dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP), S8, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252  
 dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, S8, S62, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252  
 dulaglutide, S165, S169, S172, S198, S204, S205, S206, S232,  
 duloxetine, S236  
 dyslipidemia, S12, S13, S27, S28, S47, S56, S66, S87, S96, S97, S148, S179, S180, S191, S192, S193, S202, S231, S234, S236, S248, S259–S260, **S266–S267**, S270, S272  
 e-cigarettes, S6, **S90–S91**  
 eating disorders, S82, S95, S263  
 eating patterns, S6, S44–S45, S53, S55, S68, S80, S81, **S82**, S84, S85, S93, S95, S96, S269, education, *see also* diabetes self-management education and support (DSMES).  
   on device use, **S127**  
   patient, S7, S13, S16, S120, S121, S239, S264  
   preconception, S262, S263, S273, **S282–S283**, S284  
   staff, S10, S128, S253, S297  
 electrical stimulation, gastric, S237, S240  
 ELIXA trial, S198–S199, S204  
 EMPA-REG OUTCOME trial, S200, S201, S203, S206–S207, S224  
 empagliflozin, S10, S62, S169, S172, S200–S201, S203–S204, S205, S206, S207, S224, S226, S269, S270, S271  
 EMPEROR-Preserved trial, S200–S201, S203, S207, S226  
 EMPEROR-Reduced trial, S200–S201, S203, S207, S226  
 employment, diabetes and, S308  
 enalapril, S205, S237  
 end-of-life care, S248, **S254**  
 enteral/parenteral feedings, S298, **S300–S301**  
 erectile dysfunction, S65, S235, **S237**  
 ertugliflozin, S62, S172, S200, S204, S205, S299  
 erythromycin, S237  
 erythropoietin therapy, A1C and, S22, S247  
 estimated average glucose (eAG), S112  
 ETDRS study, S233, S234  
 ethnicity, S2, S12, S15, S23, S25, S27, S28, S30, S34, S45, S62, S63, S64, S79, S112, S262, S268  
 evidence-grading system, S3  
 evolocumab, S188, S189, S190–S191  
 EXAMINE trial, S196, S197, S206  
 exenatide, S172, S198, S205, S206  
 exercise. *see* physical activity.  
 exocrine pancreas diseases, S6, S30, S69  
 EXSCEL trial, S198–S199, S205,  
 eye exam, S55, S57, S232, S267, S272, S283  
 ezetimibe, statins and, S187, **S189**, S190, S192  
 family history, S23, S25, S26, S27, S28, S32, S34, S55, S59, S62, S95, S180, S193, S268, S271  
 farmworkers, migrant and seasonal, S15–16  
 fasting, S6, S10, S20, S21, S23, S25, S35, S36, **S83**, S119, S127,  
 fasting plasma glucose (FPG) test, S20, **S21**, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S171  
 fats, dietary, S6, S81, **S85**, S154, S266, S272, S284, S285, S287,  
 FDA standards, for glucose meters, S128  
 fear, of hypoglycemia, S56, S91, S92, S93, S94, S119, S121, S159, S244, S263  
 fenofibrate, S192, S234  
 fibrates, S260, S272  
   plus statin therapy, **S192**  
 fibrosis-4 index, S65, S66, S67,  
 FIDELIO-DKD trial, S206, S209, S226, S227  
 FIGARO-DKD trial, S206, S209, S227  
 finerenone, S195, S202, **S206**, **S209–S210**, S225, S226–S227  
 fish skin graft, S240  
 FLOW trial, S266  
 fluvastatin, S188  
 food insecurity, S15  
 foot care, S9, **S237–S241**, S268  
 footwear, S90, S237, S239  
 FOURIER trial, S189  
 fracture risk, S6, S59, S60–S62, S68,  
 gastrectomy, vertical sleeve, S153  
 gastric aspiration therapy, S149  
 gastric bypass, Roux-en-Y gastric, S153  
 gastric electrical stimulation, S237  
 gastrointestinal neuropathies, **S235**  
 gastroparesis, S8, S235, **S237**, S252  
 gemfibrozil, S192  
 genetic testing, S25, S32–S33, S66  
 genitourinary disturbances, **S235**  
 gestational diabetes mellitus (GDM), S10, S23, S27, **S34–S37**, S45, S46, S47, S81, S88, S95, S97, S132, S232–S233, **S286–S288**  
   definition, S34  
   diagnosis, S35–S36  
   insulin, **S288**  
   lifestyle and behavioral management, S287  
   management of, **S286–S288**  
   medical nutrition therapy, S287  
   metformin, S287  
   one-step strategy, S35  
   pharmacologic therapy, S287–S288  
   physical activity, S287  
   postpartum care, S290  
   screening, S35–S36  
   sulfonyleureas, S287  
   two-step strategy, S37  
 glargine, S159, S162, S169, S170, S172, S173, S174, S250, S298  
 glimepiride, S169, S172, S196, S202  
 glipizide, S172, S252  
 glomerular filtration rate, S8, S9, S56, S61, S85, S119, S161, S165, S166, S167, S168, S185, S186, S195, S196, S199, S201, S219, S220, **S221**, S223, S225, S250, S267, S271  
 glucagon, S7, S8, S31, S118, **S120–S121**, S158, S169, S170, S208, S224, S225, S231,  
 glucagon-like peptide 1 receptor agonists (GLP-1 RA), S8, S28, S62, S67, S68, S116, S148, S151, S152, S160, S164, S166, S167, S171, S172, S173, S195, S196, S199, S204, S209, S220, S245, S249, S269, S270, S299  
 glucocorticoid therapy, **S301**

- glucose meters, S7, S119, S127, S128–S129  
 counterfeit strips, S128  
 inaccuracy, S129  
 interfering substances, S129  
 optimizing use of, S128  
 oxygen, S129  
 standards, S128  
 temperature, S129
- glucose monitoring. *see* blood glucose monitoring.
- glucose-6-phosphate dehydrogenase deficiency, A1C and, S22, S112,
- glucose-lowering therapy, S33, S148, S165  
 glulisine, S173, S250,  
 glyburide, S10, S172, S252, S286, S287
- glycemic goals, S7, S8, S9, S10, **S111–S125**  
 assessment of glycemic status, **S111–S113**  
 cardiovascular disease outcome with, **S116–S117**  
 continuous glucose monitoring, **S113–S114**  
 for nonpregnant adults, **S116**  
 in diabetic kidney disease, **S223**  
 in hospitalized patients, **S296–S297**  
 in pregnancy, **S284–S285**  
 hypoglycemia, **S118–S121**  
 intercurrent illness, **S121**  
 in older adults, S246–S249  
 in pediatric type 1 diabetes, **S263–S265**  
 in pediatric type 2 diabetes, **S269**  
 setting and modifying A1C goals, S117–S118
- glycemic treatment, S7, **S158–S178**  
 for adults with type 1 diabetes, S158–S164  
 for adults with type 2 diabetes, S164–S174  
 growth factors, S240  
 guanfacine, S237
- health literacy, S14, S15, **S16**, S80, S119, S247, S262, S273
- health numeracy, S13, S14, S15, **S16**, S53, S79, S80, S83, S84, S162, S247, S261
- health promotion, S11–S19
- hearing impairment, S69
- heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227
- hemodialysis, A1C and, S22, S247
- hemoglobinopathies, A1C and, S35, S44, S55, S268
- hepatitis B, S222, S284
- hepatitis B vaccines, **S56**, S58, S284
- hepatitis C infection, **S64**, S284
- hepatitis, autoimmune, S24, S265
- high-intensity interval training, S6, **S88**
- Hispanic/Latino population, S15, S22, S27, S28, S79, S87
- homelessness, S5, S14, **S15**, S55, S119, S262, S273
- hospital care, S10, **S295–S306**  
 care delivery standards, **S295–S296**  
 continuous glucose monitoring, **S297**  
 diabetes care specialists in, S296  
 diabetic ketoacidosis, **S301–S302**  
 enteral/parenteral feedings, **S300**  
 glucocorticoid therapy, **S301**  
 glucose-lowering treatment in, **S298–S299**  
 glucose monitoring, **S297–S298**  
 glycemic goals in, **S296–S297**  
 hyperosmolar hyperglycemic state, **S301–S302**  
 hypoglycemia, **S299–S300**  
 insulin therapy, S298–S299
- medical nutrition therapy in, **S301**  
 medication reconciliation, S302  
 noninsulin therapies, S299  
 perioperative care, S301  
 preventing admissions and readmissions, **S303**  
 self-management in, **S300**  
 standards for special situations, **S300–S301**  
 structured discharge communication, S302  
 transition to ambulatory setting, S295, **S302–S303**
- HOT trial, S182, S183
- housing insecurity, S5, **S15**
- HPS2-THRIVE trial, S192
- human immunodeficiency virus (HIV), S22, S23, S26–S27, **S30**, S235, S284
- human regular insulin, S170, S173, S301, S302
- hybrid closed-loop systems. *see* automated insulin delivery systems.
- hydrogel, oral, S149
- hyperbaric oxygen therapy, S239, S240
- hyperglycemia, S10, S15, S21, S22, S23, S24, S25, S26, S28, S30, S31–S32, S34, S35, S47, S63, **S64**, S67, S68, S69, S83, S86, S88, S95, S97, S111, S113, S115, S121, S127, S128, S131–S132, S135, S146, S153, S165, S168, S170, S171, S221, S231, S232, S246, S247, S248, S251, S253, S254, S261–S262, S264, S269, S272, S282, S284, S285, S286, S290, S295, S296, S297, S298–S299, S301–S302
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S36, S285
- hyperosmolar hyperglycemic state, S10, S64, S121, S247, S269, S270, S298, S301–S302
- hypertension, S9, S12, S13, S27, S28, S45, S47, S57, S65, S66, S85, S87, S88, S97, S116, S146, S148, S159, S179, **S180–S186**, S193, S199, S202, S205, S221, S222, S223, S224, S225, S227, S231, S236, S244, S247, S248, S250, S254, S259, S260, S266, S270, **S271**, S272, S282, S284, S286, S288, S289
- hypertriglyceridemia, S85, S159, S168, S191
- hypoglycemia, **S64–S65**, **S118–S125**, S129, S130–S132, S134–S135, S136, S150–S154, S158–S165, S168–S169, S170, S174, S203, S208, S210, S223, S234, S235, S244, **S245–S246**, S249–S250, S251, S252, **S253–S254**, S261–S265, S269, S282, S282–S288, S291, S295, S296–S297, S298, **S299–S300**, S301–S302
- hypogonadism, S65, S237
- hypokalemia, S186, S220, S222
- icosapent ethyl, S85, S191, S225
- idiopathic type 1 diabetes, **S27**
- illness, intercurrent, glycemic targets in, **S121**, S129
- immune checkpoint inhibitors, S23, S26
- immune-mediated diabetes, **S24**
- immunizations, **S54–S59**
- impaired fasting glucose (IFG), S21, S24, S27, S28, S43, S48
- impaired glucose tolerance (IGT), S21, S24, S27, S28, S36, S43, S47, S48
- inclisiran, S9, S187, S189–S191
- incretin-based therapies, S31, S69, **S252**
- Indian Diabetes Prevention Program (IDPP-1), S46
- infections, S5, S26, S31–S32, S54–S59, S63, S64, S90, S134, S235, S239, S251, S252, S301
- influenza vaccines, **S56–S57**, S58
- inhaled insulin, S8, S133, S158, S160, S173
- injection techniques, S133, S161, **S160–S161**
- inpatient care. *see* hospital care.
- insulin analogs, S8, S134, S158, S159, S162, S169, S170, S174, S252, S264, S298, S302
- insulin delivery, S7, S8, S57, S83, **S132–S136**  
 automated systems, S7, S8, S83, S84–S85, S97, S116, S119, S120, S126, S127, S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297  
 do-it-yourself closed-loop systems, **S135**, S159  
 injection techniques, S133, S161, **S160–S161**  
 IV, transitioning to SC, **S298–S299**  
 pens and syringes, **S132–S133**  
 pumps, **S133–S136**
- insulin pump therapy, S128, S130, S131, **S133–S136**, S160, S162, S264, S270
- insulin resistance, S22, S23, S25, S27, S28, S30, S31, S47, S62, S65, S66, S67, S87, S97, S170, S172, S272, S284, S285, S286, S287, S288, S289, S298
- insulin secretagogues, S81, S88, S89, S120, S148, **S252**
- insulin therapy  
 access and affordability, S308  
 basal, S10, S119, **S129**, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, **S170**, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302  
 cost considerations, **S173**  
 dosing algorithms using machine learning, S126, S133, S135, S222, S246, S288, S296  
 in adults with type 1 diabetes, **S158–S164**  
 in adults with type 2 diabetes, **S164–S174**  
 combination injectable, **S174**  
 concentrated insulins, **S170**, S288, S299  
 in hospitalized patients, S298–S299  
 inhaled insulin, S8, S133, S158, S160, S173  
 in older adults, S250–S253  
 prandial, S128, S160, **S170**, S171, S174, S250, S262, S270, S298, S300  
 insulin:carbohydrate ratio (ICR), S162
- integrated CGM devices, S130
- intensification  
 of obesity treatment, S8, S149  
 of diabetes therapy, S8, S160, S164, S168, S169, S174, S197, S141, S143, S149, S151, S154, S176
- intermittent fasting, S83
- intermittently scanned CGM devices, S7, S78, S94, S129–S130, **S131**, S263, S264, S269
- International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S34–S37
- islet transplantation, S161, **S164**
- isradipine, S237
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, S9, S80, S221, S224
- ketoacidosis, diabetic, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, **S301–S302**
- kidney disease. *see* chronic kidney disease.
- Kumamoto study, S116
- lactation, **S290–S291**
- language barriers, S16
- latent autoimmune diabetes in adults (LADA), S23
- Latino/Hispanic population, S15, S22, S27, S28, S79, S87

- LEADER trial, S198–S199, S204, S224  
 lifestyle behavior changes, **S44–S46**  
   delivery and dissemination of, **S45–S46**  
   Diabetes Prevention Program, **S44**  
   for diabetes prevention, **S44–S46**  
   for hypertension, **S184**  
   for lipid management, S186–S187  
   for weight management, S147–S148  
   in older adults, **S249**  
   in pediatric type 1 diabetes, S259, S266–S267  
   in pediatric type 2 diabetes, S259, **S268–S271**  
   in pregnancy, S286  
   nutrition, **S44–S45**  
   physical activity, **S45**  
   to reduce ASCVD risk factors, S180, S184  
   type 1 diabetes progression and, **S46**
- linagliptin, S172, S196, S202–S203, S206, S271  
 lipase inhibitors, S151  
 lipid management, S146, **S186–S187**, **S236**, S247, S254  
 lipid profiles, S56, S186, S187, S259–S260, S266, S267  
 liraglutide, S46, S68, S149, S151, S164, S169, S172, S173, S174, S198, S204–S205, S206, S224, S232  
 lispro, S170, S172, S173, S250  
 lixisenatide, S173, S174, S198, S204, S206  
 long-acting insulin, S159, S169, S170, S252, S264, S269, S270  
 Look AHEAD trial, S63, S69, S83, **S147**, S202, S249  
 loss of protective sensation, S235, S237, **S238**  
 lovastatin, S188
- machine learning, insulin dosing algorithms using, S296  
 macular edema, diabetic, S232–S234, S252  
 marijuana. *see* cannabis.  
 maternal history, in screening children/adolescents, S27  
 maturity-onset diabetes of the young (MODY), S23, **S32–S33**, S268  
 meal planning, S80, **S82–S83**, S84, S284  
 Medicaid expansion, S14  
 medical devices, for weight loss, **S149**  
 medical evaluation, S2, S3, S6, **S52–S76**, S146, S161, S187  
   autoimmune diseases, **S59**  
   bone health, **S59**  
   cancer, **S62**  
   cognitive impairment/dementia, **S62**  
   comorbidities, **S59–S62**  
   comprehensive, **S54**, S55–S56  
   COVID-19, **S62–S64**  
   disability, **S64**  
   hepatitis C, **S64**  
   hyperglycemia, **S64**  
   hypoglycemia, **S64–S65**  
   immunizations, **S54–S59**  
   low testosterone in men, **S65**  
   nonalcoholic fatty liver disease, **S66–S68**  
   nonalcoholic steatohepatitis, **S66–S68**  
   obstructive sleep apnea, **S68–S69**  
   pancreatitis, **S69**  
   periodontal disease, **S69**  
   sensory impairment, **S69**  
   statins, **S69**
- medical nutrition therapy, S6, S45, S54, S57, S77, **S80–S88**, S113, S128, S154, S187, S259–S260, S261, S285  
 alcohol, **S86**  
 carbohydrates, **S84–S85**  
 eating patterns and meal planning, **S82–S83**  
 fats, **S85**  
 food insecurity and access, **S82**  
 goals of, **S80**  
 in children and adolescents with type 1 diabetes, **S261**  
 in hospitalized patients, **S301–S302**  
 in pregnancy, **S287**  
 micronutrient, and supplements, **S85–S86**  
 nonnutritive sweeteners, **S86**  
 protein, **S85**  
 sodium, **S85**  
 weight management, **S80–S82**
- Mediterranean diet, S6, S45, S68, S81, S82, S85, S186  
 meglitinides, S9, S115, S117, S119, S148, S165, S172, S245, S249, S252  
 mental health. *see* Psychosocial care.  
 mental health referrals, S93, S95, S96  
 mental illness, serious, **S97**  
 metabolic surgery, S7, S8, S10, S58, S67, S68, S80, S93, S145, S146, S148, **S149**, **S153–S154**, S164, S168, **S271**  
 metformin, S10, S46–S47, S56, S61–S62, S63, S68, S86, S116, S117, S148, S161, S165, S168, S169, S170, S172, S195, S196, S198, S200, S206, S210, S224, S225, S245, **S250–S252**, S260, S269, S270–S271, S272, S286, **S287–S288**, S290, S301,  
 metoclopramide, S237  
 metoprolol, S206, S237  
 micronutrients, S80, S81, S83, **S85–S86**  
 microvascular complications, S2, S7, S12, S28, S31, S33, S48, S55, **S90**, S96, S113, **S115–S116**, S117, S159, S164, S189, S181, S234, **S267–S268**, S270, S283,  
 midodrine, S237  
 miglitol, S172  
 migrant farmworkers, S15–S16  
 mineralocorticoid receptor antagonist therapy, S8, S185, S186, S220, S222, S223, S225, **S226–S227**  
 monogenic diabetes syndromes, S22, **S32–S34**  
 multiple daily injections (MDI), S55, S128, S129, S130, S131, S132, S133–S134, S135, S160, S162–S163, S270  
 myasthenia gravis, S24, S59, S256
- naltrexone/bupropion ER, S150  
 nateglinide, S46, S172, S252  
 National Diabetes Data Group, S36  
 National Diabetes Prevention Program, S45  
 National Health and Nutrition Examination Survey (NHANES), S12, S35, S69, S268  
 neonatal diabetes, S22, **S32**, S33, S258  
 nephrologist, referral to, S220, S221, **S227**  
 nephropathy, diabetic, S10, S28, S59, S60, S62, S97, S115, S164, S186, S196, S199, S201, S203, S224–S225, S231, S238, S259, S260, **S267**, S270, **S271**, S284  
 neurocognitive function, **S245**  
 neuropathic pain, S64, S235, **S236–S237**, S268  
 neuropathy, diabetic, S9, S46, S54, S57, S59, S60, S64, S69, S86, S88, S97, S115, S116, S119, S120, S134, S169, S180, S202, **S234–S237**, S239, S259, **S267–S268**, **S272**, S284, S301  
 auditory, S69  
 autonomic, S59, S88, **S90**, S181, S234, S235, S301  
 cardiac autonomic, **S235**  
 gastrointestinal, **S235**  
 genitourinary disturbances due to, **S235**  
 peripheral, S46, S59, S64, **S78**, S86, **S90**, **S235**, S238  
 new-onset diabetes after transplantation (NODAT), S31–S32  
 niacin + statin therapy, **S192**  
 nonalcoholic fatty liver disease (NAFLD), S55, S57, **S65–S68**, S284  
 nonalcoholic steatohepatitis (NASH), S57, **S65–S68**, S167  
 noninsulin treatments, S23, S25, S32, S68, S127, **S129**, S131, S132, **S161–S164**, S168, S169, S170, S172, S249, S250, S251, S269, S286, S295, S298, **S299**, S300, S302, S308  
 noninsulin-dependent diabetes. *see* type 2 diabetes.  
 nonnutritive sweeteners, S6, S81, S86  
 NPH insulin, S159, S160, S163, S169, S170, S171, S172, S173, S174, S250, S252, S298, S300–S301  
 nucleoside reverse transcriptase inhibitors, S32  
 nursing homes, **S253–S254**  
 nutrition, S6, S11, S13, S16, S22, S30, S35,  
   for diabetes prevention/delay, **S44–S45**  
   nutrition therapy. *see* medical nutrition therapy.
- obesity, S7–S8, S9, S10, S26, S27, S28, S30, S34, S44, S48, S55, S62, S65, S66, S67–S69, S80–S81, **S145–S157**  
   assessment and monitoring, **S145–S147**  
   medical devices for weight loss, **S149**  
   metabolic surgery, **S149**, **S153–S154**  
   nutrition, physical activity, and behavioral therapy, **S147–S148**  
   pharmacotherapy, **S148–S149**, S150–S152  
 obstructive sleep apnea, S55, S56, **S68–S69**, S97, S173, S186, S199, S260, **S272**  
 ODYSSEY OUTCOMES trial, S189  
 older adults, S9, S15, S57, S58, **S244–S257**  
   bone health in, S59–S62  
   end-of-life care, S254  
   hypoglycemia, S245–S246  
   lifestyle management, S249  
   neurocognitive function, **S245**  
   pharmacologic therapy, S250–S253  
   in skilled nursing facilities and nursing homes, S253–S254  
   special considerations for, S253  
   treatment goals, S246–S249  
   with type 1 diabetes, S245, 246  
 one-step strategy, for GDM, **S35–S36**  
 opioid antagonist/antidepressant combination, S150  
 opioids, S236, S237  
 ophthalmologist, referral to, S90, S232, S233  
 oral agents. *see also specific drugs.* **S129**, S253, S254, S288  
 oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290  
 organ transplantation, posttransplantation  
   diabetes mellitus, S23, **S31–S32**  
   orlistat, S46, S150  
 orthostatic hypotension, S182, S234, S235, **S237**  
 overweight people, S9, S10, S27, S28, S30, S44, S45, S48, S67, S80, S81, S86, S87, S116, **S146–S147**, S148, S149, S180, S249, children and adolescents, S9–S10, S26, S27, **S268–270**,  
   during pregnancy, S284, S288, S290  
 oxygen, glucose monitors and, S129  
 oxygen therapy, S240  
   for advanced wound care, S240

- hyperbaric, S239, S240  
topical, S237, S239, S240–S241
- P2Y12 receptor antagonists, S193, **S195**
- palliative care, S248, S253, S254
- pancreas transplantation, S161, S164
- pancreatectomy, S31, S69, S135
- pancreatic diabetes, S6, **S30–S31**
- pancreatitis, S6, S23, S27, S30, S31, **S69**, S151–S152, S191, S205, S272
- paramedics, S14, S16, S45, S52, S79, S91, S169
- pens, insulin, S7, S126, S127, **S132–S133**
- periodontal disease, S30, **S69**
- perioperative care, S10, **S301**
- peripheral arterial disease, **S238–S239**
- peripheral neuropathy, S46, S59, S64, **S78**, S86, **S90**, **S235**, S238
- pernicious anemia, S24, S59
- person-centered care goals, S12, **S47–S48**, S12
- pharmacologic approaches. *see also* specific medications, medication classes.  
for adults with type 1 diabetes, **S158–S164**  
for adults with type 2 diabetes, **S164–S174**  
for cardiovascular and renal disease, S7 **S202–S205**, S209–S210, S227  
for comorbidities, S57  
for hypertension, S184–S186  
for lipid management, S188–S192  
for neuropathic pain, S64, S235, **S236–S237**, S268  
for obesity, S7, **S148–S149**, **S150–S153**  
for pediatric type 2 diabetes, **S269–S271**  
for smoking cessation, S90  
in older adults, **S249–S253**  
in pregnancy, **S287–S288**, S289  
interfering substances for glucose meter readings, S129  
to delay or prevent type 2 diabetes, **S46–S47**  
to delay type 1 progression, **S48**  
to glycemic treatment, S8, **S158–S178**
- phentermine, S46, S149, S150, S152, S271
- phentermine/topiramate ER, S150
- phosphodiesterase type 5 inhibitors, S237
- photocoagulation surgery, **S233–S234**
- physical activity, S6, S10, S11, S28, S55, S57, S61, S64, S111, S127, S128, S135, S202  
exercise and youth, **S87**  
for diabetes prevention, S44, **S45–S46**  
frequency and type of, **S87**  
glycemic control and, **S88**  
high-intensity interval training, **S88**  
in children with type 1 diabetes, **S261–S262**  
in children with type 2 diabetes, S269  
in DSMES, **S86–S90**  
in obesity management, **S147–S148**  
in older adults, S249  
in pregnancy, **S287**  
with diabetic kidney disease, **S90**  
with microvascular complications, **S90**  
pre-exercise evaluation, **S88**
- pioglitazone, S47, S62, S67, S68, S172
- PIONEER-6 trial, S198–S199
- pitavastatin, S188
- plasma glucose test, 2-h, S20, **S21**, S23, S24, S26, S27, S30, S33, S35
- pneumococcal pneumonia vaccine, **S57**, S58
- point-of-care assays  
A1c, S21, S22, S112  
blood glucose monitoring, S136, S297
- polycystic ovary syndrome, S27, S28, S260, S272, S273, S284, S286, S287
- population health, S5, **S11–S19**  
access to care, S14  
behaviors and well-being, S13  
care teams, S13  
chronic care model, S12–S13  
cost considerations, S13–S14  
quality improvement, S14  
recommendations, S11  
tailoring treatment for social context, S14–S16  
status and demographics, S12  
telehealth, S13
- postbariatric hypoglycemia, S154
- postpartum care, in diabetic women, **S289–S291**
- posttransplantation diabetes mellitus, S23, **S31–S32**
- pramlintide, S161, S172, S237
- prandial insulin, S128, S160, **S170**, S171, S174, S250, S262, S270, S298, S300
- pravastatin, S188
- prediabetes, S5, S10, S21  
criteria defining, S22  
diagnosis, S27–S28  
lifestyle changes for prevention of diabetes, **S44–S46**  
prevention of vascular disease and mortality, **S47**  
screening in adults, S26, S27, S28–S30  
screening in children and adolescents, S30
- preeclampsia, in women with diabetes, S34, S35, S184, S282, S284, S285–S286, 288
- aspirin and, S289
- pregabalin, S148, S236
- pregnancy, S10, **S282–S294**  
A1C and, S22, **S285–S286**  
continuous glucose monitoring in, **S286**  
drug considerations in, **S89**  
gestational diabetes mellitus (GDM), S23, **S34–S37**, **S287–S288**  
glucose monitoring in, **S285**  
glycemic goals in, **S284–S286**  
insulin physiology in, **S288**  
lactation, **S290**  
lifestyle and behavior management, **S287**  
medical nutrition therapy, **S287**  
metformin in, **S287**  
pharmacologic therapy, **S287–S288**  
physical activity in, **S287**  
postpartum care, **S289–S291**  
pre-existing type 1 and 2 diabetes in, **S288–S289**  
preconception care, **S283–S284**  
preconception counseling, **S282–S283**  
preeclampsia and aspirin, **S289**  
real-time CGM device use in, **S131–S132**  
retinopathy during, **S232–S233**  
sulfonylureas, **S287**
- prevention, type 2 diabetes, S6, S7, S9, S14, S27, S28, **S43–S51**  
lifestyle behavior change for, **S44–S43**  
person-centered care goals, **S47–S48**  
pharmacologic interventions, **S46–S47**  
of vascular disease and mortality, **S47**
- proliferative diabetic retinopathy, S90, S233
- proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, S8, S30, S187, S188, **S189**, **S190**, S192
- protease inhibitors, A1C and, S30
- protein intake, S9, S10, **S85**, S158, S220, S223, S249, S270, S271
- psychosocial care, S6, S9, S77, **S91–S98**  
anxiety disorders, **S94**
- assessment and treatment, **S92–S93**  
cognitive capacity/impairment, **S96–S97**  
depression, **S95**  
diabetes distress, **S93–S94**  
disordered eating behavior, **S95–S96**  
in pediatric type 1 diabetes, S261, **S262–S263**  
in pediatric type 2 diabetes, S273  
referral to mental health specialist, S93, S95, S96  
screening, S92  
serious mental illness, **S96**  
sleep health, S97
- pumps, insulin, **S133–S136**  
do-it-yourself closed-loop system, S135, S159  
in youth, S7, S134, S263, S270  
sensor augmented, S134
- quality improvement, S5, **S14**, S295, S299
- RAAS inhibitors, S163
- race, S22, S27, S63, S64, S79, S112, S148, S196, S198, S200, S221
- rapid-acting insulin analog, S134, S135, S159, S160, S163, S170, S173, S250, S254, S262, S285, S298, S299, S301, S302
- real-time CGM devices, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297
- REDUCE-IT trial, S85, S191
- referrals, S6, S14, S16, S66, S78  
for behavioral health professionals, S92  
for community screening, S30  
for comprehensive eye exam, S57, S267  
for food insecurity, S82  
for initial care management, S57  
for local community resources, S16  
for DSME, S54, S57, S78, S79  
for tobacco cessation, S54  
from dentist to primary care, S57  
to behavioral health provider, S92, S93  
to foot care specialist, S239  
to gastroenterologist, S65, S69  
to mental health professional, S93, S95, S96  
to nephrologist, S220, S221, **S227**  
to neurologist, S235  
to sleep specialist, S98, S260  
to registered dietitian nutritionist, S45, S57, S149, S261, S265, S283, S302
- registered dietitian nutritionist (RDN), S45, S57, S80, S82, S282, S285, S287, S288 43, S255, S257, S274
- reimbursement, S14, S45  
for CGM in adults with type 2 diabetes, S9  
for DSMES, S6, S78, **S79**
- religious fasting, **S83**
- repaglinide, S172, S252
- resistance training, S45, S68, S88, S249
- respiratory syncytial virus (RSV) vaccine, S57–S58
- retinopathy, diabetic, S66, S90, S115, S227, **S231–S234**, S267, S272, S283  
screening, S232–S233  
treatment, S233–S234  
visual rehabilitation, S234
- REWIND trial, S198–S199, S204
- risk calculator, for ASCVD, **S180**
- risk management  
cardiovascular disease, S8, **S179–S218**  
chronic kidney disease, S9, **S219–S230**
- risk, screening for  
type 1 diabetes, S26  
prediabetes and type 2, S27, S29  
rivaroxaban, S193, S194

- rosiglitazone, S148  
Roux-en-Y gastric bypass, S153
- SAVOR-TIMI trial, S196, S206  
saxagliptin, S172, S196, S206, S299  
schizophrenia, S96  
schools, diabetes care in, **S127**, S261, **S262**, S263, S268, S308  
screening, S5, S6, S7, S9  
  after acute pancreatitis, S31  
  by age, S30,  
  community, S30  
  for cystic fibrosis-related diabetes, S31  
  for gestational diabetes mellitus, S34, S36  
  for neuropathy, S235–S236  
  for prediabetes and type 2 diabetes, S26–S30  
  for type 1 diabetes, S26  
  for type 2 diabetes, S27 **S240**  
  in children/adolescents, S30  
  in dental practices, S30, S55, S57  
  in people with HIV, S30  
  medications, S30  
  testing interval, S30  
  use of A1C for, S21–S22  
  use of FPG or 2-h PG for, S21  
seasonal farmworkers, S15–S16  
self-monitoring of blood glucose (SMBG). *see* blood glucose monitoring (BGM)  
semaglutide, S8, S46, S68, S148, S149, S150, S165, S168, S169, S172, S198–S199, S204, S205, S206, S224–S225, S226, S232, S252  
sensor-augmented pumps, S134  
sensory impairment, S69  
setmelanotide, S149  
sexual dysfunction, S235  
sickle cell disease, A1C and, S22, S112, S284  
simvastatin, S188, S189, S192  
sitagliptin, S169, S172, S196, S206  
skilled nursing facilities, S251, **S253–S254**  
sleep health, S7, **S97–S98**  
smart pens. *see* connected insulin pens  
smoking cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**  
social capital, S5, S14, **S15**  
social context, S14–S16  
social determinants of health (SDOH), S12, S13, S14–S15, S16, S79, S92, S166  
sodium channel blockers, S235, **S236**  
sodium intake, S81, S84, **S85**, S184, S223  
sodium-glucose cotransporter 2 (SGLT2) inhibitors, S8, S28, S62, S68, S84, S116, S148, S164, S166, S167, S172, S180, S195, S201, S209, S220, S222, S225, S246, S250, **S252**, S270, S299  
SOLOIST-WHF trial, S208  
sotagliflozin, S206, S207, **S208**  
SPRINT trial, S181, S182, S183, S205  
staging  
  of diabetic kidney disease, S57, **S221–S222**  
  of type 1 diabetes, S24  
statin therapy, S8, S9, S47, S67–S68, S116, S180, S187, **S187–S192**,  
  combination therapy with, S190–S191  
  diabetes risk with, **S192**  
  high- and moderate intensity, S188  
  intolerance to, S190  
  primary prevention, **S187**, **S188**  
  secondary prevention, **S188–S189**  
  with bempedoic acid, S8, S187, **S191**  
  with ezetimibe, S189  
  with fibrate, S169, **S170**, **S192**  
  with niacin, S169, **S170**  
  with PCSK9 inhibitors, S189–S190  
statins, S26, S30, **S57**, **S69**, S85, S192, S197, S198, S202  
stem cell therapies, for wounds, S240  
strength training, S44, S269  
sulfonylureas, S9, S15, S32, S33, S62, S68, S113, S115, S116, S117, S119, S120, S148, S165, S168, S172, S174, S245, S249, S250, S252, **S287**  
supplements, dietary, S61, S81, **S85–S86**, S141, S148, S154, S283, S284  
surveillance  
  behavioral risk factor surveillance system, S79, S94  
  BGM system, S128  
  for foot problems, S237, S238–S239  
  of chronic kidney disease, **S222–S223**  
  of NAFLD patients, S66  
SUSTAIN-6 trial, S198–S199, S204, S224  
sweeteners, nonnutritive, S6, S81, S86  
sympathomimetic amine anorectics, S150  
  in combination with antiepileptic, S150  
syringes, insulin, **S132–S133**
- tapentadol, **S236**  
technology, diabetes, S7, S8, S13, **S126–S144**  
  blood glucose monitoring, **S127–S129**  
  continuous glucose monitoring devices, **S129–S132**  
  general device principles, **S126–S127**  
  insulin delivery, **S132–S137**  
technology-assisted prevention programs, S44, S45–S46, S79, S94  
TECOS trial, S196, S206  
TEDDY study, S26, S46  
telehealth, S6, **S13**, S15, S45, S78–S80, S286  
temperature  
  of glucose monitor, S129  
  perception of, S56, S234, S235, S237, S238  
teplizumab, S48  
testing interval, S30  
testosterone  
  in diabetes prevention, S46  
  low, in men, **S65**  
tetanus, diphtheria, pertussis (TDAP) vaccine, S58, S284  
thiazide-like diuretics, S185, S186, S224  
thiazolidinediones, S46, S59, S60, S148, S165, S206, S245, **S252**  
thyroid disease  
  autoimmune, S33, S59, S266  
  in pediatric type 1 diabetes, S259, **S265**  
time-restricted eating, S83  
tirzepatide, S46, S62, S68, S148, S149, S152, S165, S168, S169, S172, S252  
tobacco use/cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**  
training  
  blood glucose awareness, S121  
  health professionals/staff, S10, S13, S16, S79  
  high-intensity interval, S6, **S88**  
  on device use, S10  
  resistance, S6, S44, S45, S68, S79, S88  
  self-care, S16  
  strength, S44, S269  
tramadol, **S236**  
transfusion, A1C and, S22, S112, S247  
transition  
  from hospital to ambulatory setting, S295, **S302–S303**  
  from IV to SC insulin, **S298–S299**  
  from pediatric to adult care, S258, **S273–S274**  
transplantation  
  islet, S161, **S164**  
  liver, S65, S66  
  organ, post-transplant diabetes mellitus after, S23, **S31–S32**  
  pancreas, S161, **S164**  
  renal, S161, S164, S196, S201, S207, S208, S221, S225  
tricyclic antidepressants, S148, S235, **S236**  
TWILIGHT trial, S194  
two-hour plasma glucose (2-h PG) test, S20, **S21**, S23, S24, S26, S27, S30, S33, S35  
two-step strategy, for GDM, **S36**  
type 1 diabetes, S5, S6, S7, S8, S9, S10, S13, S14  
  beta-cell replacement therapy, S161, S164  
  in children/adolescents, **S233–S240**  
  classification, S22–S23  
  diagnosis, **S24–S26**  
  idiopathic, S27  
  immune-mediated, **S24**, **S26**  
  in hospitalized patients, S296, **S298**, S300  
  lifestyle and progression of, S46  
  insulin therapy, S158, **S159–S160**  
  noninsulin treatments, **S161**, **S164**  
  in older adults, S245, 246  
  peripheral neuropathy in, S234–S236  
  pregnancy in women with preexisting, S283, S284, S285, S286, **S288**, S290  
  retinopathy in, S232  
  screening, S26  
  staging, S24  
  subcutaneous insulin regimens, S159–S161, S163–S164  
  surgical treatment, **S164**  
  teplizumab to delay symptoms. S48  
type 2 diabetes, S5, S6, S7, S8, S9, S10, S12, S13, S15, S22–S23  
  in children/adolescents, **S268–S273**  
  classification, **S20–S22**  
  combination therapy, S8, S164, S165, **S168–S169**, **S190–S191**, **S192**, S193, **S194**, S205, S237, S252  
  diagnosis, **S26–S31**  
  insulin pump use in, S135  
  obesity and weight management, S29, S67, **S145–S157**, S165, S168  
  pharmacologic treatment in adults, **S164–S174**  
  pregnancy in women with preexisting, **S288–S289**  
  prevention or delay, S6, S7, S9, S14, S27, S28, **S43–S51**  
  retinopathy in, S233  
  risk test for, S29  
  screening in asymptomatic adults, S27, S28, S29  
  screening in children/adolescents, S28, S30  
  surgical treatment for, S164  
type 3c diabetes, S30
- UK Prospective Diabetes Study (UKPDS), S116, S117, S197, S205  
ulcers, foot, S9, S56, S88, S90, S234, **S237–S241**  
ultra-rapid-acting insulin analogs, S159, S160, S163  
ultrasound wound debridement, S240
- vaccines. *see* immunizations.  
vagus nerve stimulator, S149  
vascular disease, S90, S116, S117, S181, S183, S192, S194, S202, S237  
  prevention of, in prediabetes, **S47**  
VERIFY trial, S168

- vertical sleeve gastrectomy, S153  
VERTIS CV trial, S200, S201, S204  
Veterans Affairs Diabetes Trial (VADT), S64, S116, S246  
vildagliptin, S168  
vitamin D supplementation, S46, S56, S60, S61, S81, S85–S86, S148  
VOYAGER-PAD trial, S194
- weight loss surgery. *see* metabolic surgery.  
weight loss/management, S7, S8, S31, S31, **S80–S82**, S83, S86, S87, S93, S96, S117, S136, **S145–S154**, S184, S186, S202, S236,  
in diabetes prevention, S44–S46, S47, S48  
in children/adolescents, S269, S271, S272  
in older adults, S249, S251, S252  
in pregnancy, S290  
in type 1 diabetes, S46, S61, S161  
in type 2 diabetes, S29, S67, S165, S168  
medical devices for, **S150**  
metabolic surgery for, **S149, S153–S154**  
pharmacotherapy for, **S148–S149**, S150–S152  
with NAFLD, S67–S68
- unexpected, S21, S23, S20, S24, S28, S62, S95, S253  
well-being, S6, **S13**, S35, S53, S65, **S77–S110**, S146, S234, S263  
whites, non-Hispanic, S22, S25, S27, S60, S63, S112, S196, S198, S200,  
WISDM trial, S246  
Wound therapy, advanced, S239–S241
- Youth. *see* Children and adolescents.
- zoster vaccine, S59